Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

Biodegradable weekly implant delivers stable levodopa levels, aiming to streamline Parkinson’s care while reshaping drug ...

The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.

The company estimated that more than 1000 women in Scotland at very high risk of fracture would be eligible for treatment.

Two examples of FDA-approved intracameral implants are Durysta (Allergan) and iDoseTR (Glaukos), both of which provide ...

The agency’s Executive Steering Group on Shortages and Safety of Medicinal Products has issued recommendations to address ...

Trump’s tax bill could reshape drug R&D, manufacturing, Medicaid access, clinical trials, and biotech funding, impacting ...

Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR ...

Hikma Pharmaceuticals. Hikma Pharmaceuticals USA Announces $1 Billion of New US Investment to Further Expand its Domestic Manufacturing and Development of Essential Generic Medicines. Press Release.

FDA says the move boosts regulatory transparency, offering insights into common approval barriers in drug applications and reducing guesswork.

Siemens expands AI-driven pharma software portfolio, integrating Dotmatics’ platform to connect drug research, development, ...

The selection of an appropriate salt form for a potential drug candidate is an opportunity to modulate its characteristics to improve bioavailability, stability, manufacturability, and patient ...